168 related articles for article (PubMed ID: 27009856)
1. mTOR regulates proteasomal degradation and Dp1/E2F1- mediated transcription of KPNA2 in lung cancer cells.
Wang CI; Chen YY; Wang CL; Yu JS; Chang YS; Yu CJ
Oncotarget; 2016 May; 7(18):25432-42. PubMed ID: 27009856
[TBL] [Abstract][Full Text] [Related]
2. Quantitative proteomics reveals regulation of karyopherin subunit alpha-2 (KPNA2) and its potential novel cargo proteins in nonsmall cell lung cancer.
Wang CI; Chien KY; Wang CL; Liu HP; Cheng CC; Chang YS; Yu JS; Yu CJ
Mol Cell Proteomics; 2012 Nov; 11(11):1105-22. PubMed ID: 22843992
[TBL] [Abstract][Full Text] [Related]
3. Karyopherin α2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer.
Drucker E; Holzer K; Pusch S; Winkler J; Calvisi DF; Eiteneuer E; Herpel E; Goeppert B; Roessler S; Ori A; Schirmacher P; Breuhahn K; Singer S
Cell Commun Signal; 2019 Nov; 17(1):159. PubMed ID: 31783876
[TBL] [Abstract][Full Text] [Related]
4. E2F1 and E2F7 differentially regulate KPNA2 to promote the development of gallbladder cancer.
Xiang S; Wang Z; Ye Y; Zhang F; Li H; Yang Y; Miao H; Liang H; Zhang Y; Jiang L; Hu Y; Zheng L; Liu X; Liu Y
Oncogene; 2019 Feb; 38(8):1269-1281. PubMed ID: 30254209
[TBL] [Abstract][Full Text] [Related]
5. IRF1 Negatively Regulates Oncogenic KPNA2 Expression Under Growth Stimulation and Hypoxia in Lung Cancer Cells.
Huang JX; Wu YC; Cheng YY; Wang CL; Yu CJ
Onco Targets Ther; 2019; 12():11475-11486. PubMed ID: 31920336
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression.
Li XL; Jia LL; Shi MM; Li X; Li ZH; Li HF; Wang EH; Jia XS
J Transl Med; 2013 Sep; 11():232. PubMed ID: 24070213
[TBL] [Abstract][Full Text] [Related]
7. Quantitative proteomics reveals a novel role of karyopherin alpha 2 in cell migration through the regulation of vimentin-pErk protein complex levels in lung cancer.
Wang CI; Wang CL; Wu YC; Feng HP; Liu PJ; Chang YS; Yu JS; Yu CJ
J Proteome Res; 2015 Apr; 14(4):1739-51. PubMed ID: 25728791
[TBL] [Abstract][Full Text] [Related]
8. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
[TBL] [Abstract][Full Text] [Related]
10. Importin subunit alpha-2 is identified as a potential biomarker for non-small cell lung cancer by integration of the cancer cell secretome and tissue transcriptome.
Wang CI; Wang CL; Wang CW; Chen CD; Wu CC; Liang Y; Tsai YH; Chang YS; Yu JS; Yu CJ
Int J Cancer; 2011 May; 128(10):2364-72. PubMed ID: 20658535
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression.
Kim YS; Jin HO; Seo SK; Woo SH; Choe TB; An S; Hong SI; Lee SJ; Lee KH; Park IC
Biochem Pharmacol; 2011 Aug; 82(3):216-26. PubMed ID: 21601561
[TBL] [Abstract][Full Text] [Related]
12. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
[TBL] [Abstract][Full Text] [Related]
13. Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non-small cell lung cancer.
Chen YF; Pang YC; Wang HC; Wu PE; Chen ZJ; Huang D; Peng DL; Yan YM; Liu C; Wu LC; Fan XZ; Cheng YX; Liu YQ
Br J Pharmacol; 2024 Apr; 181(8):1221-1237. PubMed ID: 37926864
[TBL] [Abstract][Full Text] [Related]
14. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
15. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
Morgillo F; Woo JK; Kim ES; Hong WK; Lee HY
Cancer Res; 2006 Oct; 66(20):10100-11. PubMed ID: 17047074
[TBL] [Abstract][Full Text] [Related]
16. Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer.
Lv T; Wang Q; Cromie M; Liu H; Tang S; Song Y; Gao W
Oncotarget; 2015 Oct; 6(32):33006-18. PubMed ID: 26360779
[TBL] [Abstract][Full Text] [Related]
17. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
18. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression.
Zheng Y; Ritzenthaler JD; Roman J; Han S
Am J Respir Cell Mol Biol; 2007 Dec; 37(6):681-90. PubMed ID: 17600315
[TBL] [Abstract][Full Text] [Related]
19. E2F1-mediated repression of WNT5A expression promotes brain metastasis dependent on the ERK1/2 pathway in EGFR-mutant non-small cell lung cancer.
Li H; Tong F; Meng R; Peng L; Wang J; Zhang R; Dong X
Cell Mol Life Sci; 2021 Mar; 78(6):2877-2891. PubMed ID: 33078208
[TBL] [Abstract][Full Text] [Related]
20. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
